New data from Roche’s Genentech unit suggests that a phase 3 trial of Alzheimer’s drug crenezumab is on the right track, at an optimum dose for patients in early stages of the disease.
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter. Total revenues ...
Reaching for the first sleep aid you find when insomnia hits? Not all sleeping pills are the same. Each class of sleep aid works a bit differently from the other, and side effects vary.